Aeglea BioTherapeutics, Inc.

NASDAQ:AGLE

12.01 (USD) • At close November 27, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202220212020201920182017201620152014
Revenue 2.32918.739003.8885.2054.6286.0850
Cost of Revenue 000000000
Gross Profit 2.32918.739003.8885.2054.6286.0850
Gross Profit Ratio 110011110
Reseach & Development Expenses 58.57957.06959.63864.636.71922.81518.14311.4536.83
General & Administrative Expenses 28.53127.31921.84315.73412.63210.0668.3915.9472.074
Selling & Marketing Expenses 000000000
SG&A 28.53127.31921.84315.73412.63210.0668.3915.9472.074
Other Expenses -0.007-0.122-0.005-0.063-0.057-0.042-0.036-0.0020
Operating Expenses 87.1184.38881.48180.33449.35132.88126.53417.48.904
Operating Income -84.781-65.649-81.481-80.334-45.463-27.676-21.906-11.315-8.904
Operating Income Ratio -36.402-3.50300-11.693-5.317-4.733-1.8590
Total Other Income Expenses Net 0.83-0.0110.5882.08-0.057-0.042-0.0360.02-1.443
Income Before Tax -83.951-65.66-80.893-78.254-44.348-27.236-21.698-11.295-10.347
Income Before Tax Ratio -36.046-3.50400-11.406-5.233-4.688-1.8560
Income Tax Expense -0.1360.141-0.593-2.561-0.057-0.731-0.244-0.0221.443
Net Income -83.815-65.801-80.3-75.693-44.348-27.236-21.698-11.295-10.347
Net Income Ratio -35.988-3.51100-11.406-5.233-4.688-1.8560
EPS -24.86-25.02-37.61-59.23-53.25-45.01-55.4-24.71-37.93
EPS Diluted -24.86-25.02-37.61-59.23-53.25-45.01-55.4-24.71-37.93
EBITDA -84.781-65.649-80.485-80.334-44.055-27.676-21.774-11.226-7.441
EBITDA Ratio -36.402-3.50300-11.331-5.317-4.705-1.8450